Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated radiotherapy + PD-1 inhibitor + GM-CSF for refractory head and neck tumors (Prague-1.0)
ChiCTR2300068665Phase 2Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in head and neck cancer (HNC), head and neck squamous cell carcinoma (HNSCC), adenoid cystic carcinoma of the oral cavity (ACC) and 1 more, sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Objective response rate (ORR). Planned start Jan 2023; status: not yet recruiting.
02
Drugs
sargramostim
03
Conditions
head and neck cancer (HNC)head and neck squamous cell carcinoma (HNSCC)adenoid cystic carcinoma of the oral cavity (ACC)head and neck sarcoma
Beyond the preview
Go deeper on ChiCTR2300068665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068665.